Key result
A 6-month ablation endpoint accurately predicts 12-month success with ~88% concordance.
Why the study?
Does a shortened 6-month effectiveness endpoint (inclusive of a 2-month blanking period) agree with and reliably predict the standard 12-month effectiveness endpoint in clinical trials of catheter ablation for paroxysmal atrial fibrillation?
Meta-Analysis (n=905)
Yes
Does a shortened 6-month effectiveness endpoint (inclusive of a 2-month blanking period) agree with and reliably predict the standard 12-month effectiveness endpoint in clinical trials of catheter ablation for paroxysmal atrial fibrillation?
Shortening the postablation follow-up endpoint to 6 months (with a 2-month blanking period and a 56.2% performance goal) provides high concordance with 12-month outcomes and accurately predicts 1-year effectiveness via linear extrapolation, potentially reducing trial duration and cost.
Answers are grounded in this paper and cite their sources.
Supports 6-month endpoints in paroxysmal AF ablation trials; extends efficient designs with accurate 12-month outcome prediction.
BACKGROUND: Evidence regarding the use of a 6-month effectiveness end point for trials of atrial fibrillation ablation is limited. This study aims to evaluate the relationship between ablation effectiveness end point detection and follow-up duration, with the secondary goal of informing the design of clinical trials of paroxysmal atrial fibrillation ablation. METHODS: Patient-level data from 4 prospective studies were aggregated. Long-term effectiveness end points were calculated with (1) a 3-month blanking period and 12-month follow-up (current) and (2) a 2-month blanking period and 6-month follow-up (proposed). Sensitivity, specificity, and agreement were calculated for each study under the current and proposed end points. A linear approximation method was used to extrapolate the 6-month survival estimate to 12 months, and the predicted 12-month survival rates were compared with the actual 12-month survival rates. Using the linear approximation, a new performance goal was derived and compared against the 6-month survival of each study. RESULTS: The comparative analysis between the current and proposed end points demonstrated concordances ranging from 83% to 92% and sensitivities ranging from 57% to 76% across the 4 recent clinical trials. The linear approximation method produced an estimated 12-month survival rate of the 4 pooled studies of 72.5%, compared with the true 12-month survival rate of 71.0% (-1.5% error). When compared against the true 12-month survival rate in each study individually, the estimated 12-month survival rate resulted in errors ranging from -3.6% to 0.3%. A new performance goal of 56.2% is proposed for trials using a 6-month end point. CONCLUSIONS: The proposed end point of a 6-month follow-up duration, inclusive of a 2-month blanking period, demonstrated reasonable levels of agreement with the current 12-month effectiveness end point. Enabling historical comparison, a 12-month survival rate can be reliably extrapolated from a 6-month survival rate using linear approximation.
No takes yet. Share an insight, caveat, or question.
Andrade et al. (2026) conducted a meta-analysis in Antiarrhythmic drug-refractory paroxysmal atrial fibrillation (n=905). Proposed 6-month effectiveness endpoint (2-month blanking period and days 61-180 evaluation) with linear approximation extrapolation vs. Current 12-month effectiveness endpoint (3-month blanking period and days 91-365 evaluation) was evaluated on 12-month freedom from long-term effectiveness failure (AF/AT/AFL recurrence, new or escalated antiarrhythmic drug, >1 repeat ablation during blanking, any repeat ablation during evaluation, or direct cardioversion). A proposed 6-month catheter ablation effectiveness endpoint demonstrated 83% to 92% concordance with the 12-month endpoint and predicted pooled 12-month survival at 72.5% versus 71.0% actual.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: